Evidence-backed
Scalable
Secure
This is the power of using a platform. A platform that learns and grows.
Today it serves more than 1 million patients and builds on their daily interactions.
With HealthMachine™ the answer to all of these questions is yes.
Problem Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening condition, for which there is no cure and therefore requires constant management by patients. Avegen was given the task to set-up a digital health solution that will support patient self-management and improve the patient-clinician connect. The goal of PAH management is to maintain low-risk […]
STOP (Successful Treatment Of Paranoia) is a patient-facing app that aims to reduce clinical symptoms of paranoia, in patients with mild to moderate paranoia. It is a self-administered 12-week programme using Cognitive Bias Modification for Interpretation therapy (CBM-I). Avegen in collaboration with King’s College London designed and set up STOP, the smartphone version of the therapy.
Klick is a digitally-enabled HIV care pathway conceptualised by Chelsea and Westminster Hospital Foundation Trust (CWFT), Avegen and a major pharmaceutical company. Klick was designed and built by Avegen to integrate with and enhance CWFT’s outpatient service model, whilst delivering a positive experience for patients.
Engagement Lead
Patient
Pregnant mother
Regional Digital Stakeholder Engagement Lead
Get in touch to see how you can use HealthMachine™ to deliver a transformative digital health product to your patients in under 3 months.
Problem Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening condition, for which there is no cure and therefore requires constant management by patients. Avegen was given the task to set-up a digital health solution that will support patient self-management and improve the patient-clinician connect. The goal of PAH management is to maintain low-risk […]
STOP (Successful Treatment Of Paranoia) is a patient-facing app that aims to reduce clinical symptoms of paranoia, in patients with mild to moderate paranoia. It is a self-administered 12-week programme using Cognitive Bias Modification for Interpretation therapy (CBM-I). Avegen in collaboration with King’s College London designed and set up STOP, the smartphone version of the therapy.
Klick is a digitally-enabled HIV care pathway conceptualised by Chelsea and Westminster Hospital Foundation Trust (CWFT), Avegen and a major pharmaceutical company. Klick was designed and built by Avegen to integrate with and enhance CWFT’s outpatient service model, whilst delivering a positive experience for patients.